Singapore markets close in 2 hours 58 minutes

ADC Therapeutics SA (ADCT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.67-1.07 (-6.80%)
At close: 04:00PM EST
14.67 -0.03 (-0.20%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close15.74
Open15.80
Bid14.50 x 800
Ask0.00 x 900
Day's range14.65 - 16.10
52-week range13.34 - 32.00
Volume141,619
Avg. volume192,750
Market cap1.126B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-3.28
Earnings date16 Mar 2022 - 21 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est43.71
  • Business Wire

    ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022

    LAUSANNE, Switzerland, January 20, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced it will host a webcast highlighting its ADC platform and solid tumor pipeline on Tuesday, February 8, from 9:00 to 11:00 a.m. ET.

  • Business Wire

    ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

    LAUSANNE, Switzerland, January 18, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of ZYNLONTA® (loncastuximab tesirine-lpyl) for all hema

  • Business Wire

    ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

    LAUSANNE, Switzerland, November 09, 2021--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16th at 11:20 a.m. GMT / 6:20 a.m. EST.